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Abstract
APPL1 is an adaptor protein that binds to both AKT and
adiponectin receptors and is hypothesised to mediate the
effects of adiponectin in activating downstream effectors
such as AMP-activated protein kinase (AMPK). We aimed
to establish whether APPL1 plays a physiological role in
mediating glycogen accumulation and insulin sensitivity
in muscle and the signalling pathways involved. In vivo
electrotransfer of cDNA- and shRNA-expressing constructs
was used to over-express or silence APPL1 for 1 week in
single tibialis cranialis muscles of rats. Resulting changes
in glucose and lipid metabolism and signalling pathway
activation were investigated under basal conditions and
in high-fat diet (HFD)- or chow-fed rats under hyper-
insulinaemic–euglycaemic clamp conditions. APPL1 over-
expression (OE) caused an increase in glycogen storage and
insulin-stimulated glycogen synthesis in muscle, accompanied
by a modest increase in glucose uptake. Glycogen synthesis
during the clamp was reduced by HFD but normalised
by APPL1 OE. These effects are likely explained by APPL1
OE-induced increase in basal and insulin-stimulated phos-
phorylation of IRS1, AKT, GSK3b and TBC1D4. On the
contrary, APPL1 OE, such as HFD, reduced AMPK and
acetyl-CoA carboxylase phosphorylation and PPARg coacti-
vator-1a and uncoupling protein 3 expression. Furthermore,
APPL1 silencing caused complementary changes in glycogen
storage and phosphorylation of AMPK and PI3-kinase
pathway intermediates. Thus, APPL1 may provide a means
for crosstalk between adiponectin and insulin signalling
pathways, mediating the insulin-sensitising effects of adipo-
nectin on muscle glucose disposal. These effects do not appear
to require AMPK. Activation of signalling mediated via
APPL1 may be beneﬁcial in overcoming muscle insulin
resistance.
Journal of Endocrinology (2011) 210, 81–92
Introduction
Resistance of skeletal muscle to the action of insulin is an
essential pre-requisite for the development of type 2 diabetes
and is frequently associated with obesity (Zimmet et al. 2001).
This insulin resistance has been characterised by lipid-induced
impairments in glucose disposal, glycogen synthesis and lipid
use in muscle and in the associated signalling pathways
(Hegarty et al. 2003). The identiﬁcation of key molecular
mediatorsofnormalmetabolismandobesity-associatedinsulin
resistance is thus essential to underpin the development of
novelpharmacologicalapproachestothetreatmentofdiabetes.
Adiponectin (AdipoQ, Acrp30) is an adipokine that is
secreted in a mixture of trimeric, hexameric (low molecular
weight)and12–18mer(highmolecularweight,HMW)forms
(Tsao et al. 2003). It is now well established that there is an
inverserelationshipbetweentotalplasmaadiponectin,or more
particularly HMW adiponectin, and degree of adiposity or
whole-bodyinsulin resistance (Pajvanietal.2004,Lara-Castro
etal.2006).However,adiponectincirculatesataconcentration
of5–10 mg/ml(Weyer etal.2001),ordersofmagnitudegreater
than the levels of other insulin-sensitising adipokines, such
as leptin (Segal et al. 1996). Thus, it is uncertain whether
the relatively modest variations in the circulating level are of
physiological signiﬁcance or whether the primary regulation
of adiponectin action occurs at the target tissue.
A direct role for adiponectin to increase both fatty acid
oxidation and glucose disposal into skeletal muscle (Yamauchi
et al. 2002, Yoon et al. 2006) and additionally to improve
insulin sensitivity (Yamauchi et al. 2001) has been proposed,
effects that have been shown to be impaired as a result of
obesity (Bruce et al. 2005, Chen et al. 2005, Mullen et al.
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bolic end points have been shown to be primarily mediated
through activation of the energy sensing molecule AMP-
activated protein kinase (AMPK; Tomas et al. 2002, Yamauchi
et al. 2002, Yoon et al. 2006). AMPK activation is reported to
occur after binding of adiponectin to a pair of adiponectin
receptors (AdipoRs) located on the plasma membrane, with
AdipoR1 being the predominant isoform expressed in muscle
(Yamauchi et al. 2003). Although until recently the signalling
pathway linking receptor binding to activation of effector
molecules has been poorly characterised, recently published
data implicate a ceramidase activity of the receptors in the
improvement of insulin sensitivity through a reduction in
intracellular ceramide accumulation (Holland et al. 2010).
Adaptor protein containing pleckstrin homology domain,
phosphotyrosine-binding domain and leucine zipper motif
(APPL1) has been proposed on the basis of in vitro studies
to be a key node linking adiponectin binding to AdipoRs
with activation of downstream effector molecules (Mao et al.
2006). APPL1 is thought to act as a dynamic scaffold for
endosomal signalling proteins (Miaczynska et al. 2004, Chial
et al. 2008) and was ﬁrst identiﬁed as an interacting partner
for the serine/threonine kinase AKT2 (Mitsuuchi et al. 1999).
AKT2 is required for the full effect of insulin on glucose
disposal and glycogen synthesis in muscle (Cho et al. 2001,
Cleasby et al. 2007) and an interaction with APPL1 is
necessary for this process (Saito et al. 2007). APPL1 was also
shown to interact with AdipoRs in response to adiponectin,
causing increased AMPK phosphorylation and translocation
of GLUT4 to the plasma membrane of C2C12 myotubes
(Mao et al. 2006). Furthermore, the synergistic effect of
adiponectin and insulin treatment on AKT activation was
abolished by APPL1 down-regulation in these cells (Mao et al.
2006). These data suggest that APPL1 may provide a means
for crosstalk between adiponectin and insulin signalling
pathways and thus a potential mechanism for the insulin-
sensitising effect of adiponectin. However, the role of APPL1
in determining glucose disposal and storage as glycogen in
muscle and the signalling pathways involved have not been
investigated in a physiologically relevant in vivo setting.
In this study, we aimed to establish whether APPL1 has a
physiological role in skeletal muscle metabolism in vivo,
whether increasing APPL1 expression would be sufﬁcient to
overcome high-fat diet (HFD)-induced insulin resistance and
the signalling pathways implicated in this.
Materials and Methods
Materials
General reagents were supplied by Sigma–Aldrich and
molecular reagents by Promega, Invitrogen or New England
Biolabs (Genesearch, Arundel, Australia). The APPL1
antibody used was as described previously (Cheng et al.
2007). The APPL2 antibody was from Abnova (Heidelberg,
Germany), pY608-IRS1 antibody was from Biosource
International (Camarillo, CA, USA), uncoupling protein
(UCP) 3 antibody from Thermo Scientiﬁc (Rockford, IL,
USA), total IRS1 and anti-peroxisome proliferator-activated
receptor gamma coactivator (PGC) 1a from Calbiochem
(Merck Chemicals), total GSK3a/b and pT642-TBC1D4
antibodies from Millipore (Billerica, MA, USA), GFP
antibody from Molecular Probes (Leiden, The Netherlands),
anti-FLAG and actin antibodies from Sigma, and all others
from Cell Signaling Technology (Beverley, MA, USA).
Vector construction
The Gateway-converted (Invitrogen) skeletal muscle-speciﬁc
mammalian expression vector EH114-GW (Cleasby et al.
2007), the Donor vector pDONR201-BSIIMCS (Cleasby
et al. 2007), EH114-EGFP (Cleasby et al. 2005) and the
FLAG-tagged APPL1 cDNA contained within pEGFP
(Cheng et al. 2007) have previously been described. To
obtain EH114-APPL1, pEGFP-APPL1 was digested with
HindIII and KpnI, the 2.1k bAPPL1 cDNA fragment ligated
into similarly digested pDONR201-BSIIMCS and recombi-
nation into EH114-GW performed by LR Clonase II.
Correct insertion was conﬁrmed by restriction digest and
sequencing; two shRNA sequences targeting distinct regions
of the APPL1 mRNA and a scrambled sequence cloned into
the pSUPER vector (OligoEngine, Seattle, WA, USA) were
obtained from Dr Paul Pilch (Saito et al. 2007). The second
shRNA clone, which was not previously described, has
targeting sequence GCTGGATACCTAAATGCTAGG.
Animals
All experimental procedures were approved by the Garvan
Institute Animal Experimentation ethics committee and
were in accordance with the National Health and Medical
Research Council of Australia Guidelines on Animal
Experimentation or were carried out under UK Home
Ofﬁce licence to comply with the Animals (Scientiﬁc
Procedures) Act 1986.
Male Wistar rats (w150 g) were obtained from the Animal
Resources Centre (Perth, Australia) or Charles River
(Margate, UK). Animals were maintained at 22G0.5 8C
under a 12h light:12h darkness cycle and were fed a
standard maintenance chow diet (Gordon’s Specialty Feeds,
Yanderra, Australia or Lillico, Betchworth, UK) (8% fat, 21%
protein and 71% carbohydrate as a percentage of total dietary
energy), made available ad libitum. Where a HFD was
employed, half of the subject animals were fed a homemade
diet contributing 45% of calories from fat (lard), 20% from
protein and 35% from carbohydrate (4.7 kcal/g) for 5 weeks,
made available ad libitum, a period demonstrated to generate
muscle insulin resistance in the absence of overt obesity
(Bruce et al. 2008). Before 1 week of hyperinsulinaemic–
euglycaemic clamp (HEC) study, both jugular veins of rats
were cannulated, as described previously (10). Rats were
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for the following week. Isoﬂurane anaesthesia was supple-
mented with local bupivacaine irrigation (0.5 mg/100 g) and
5 mg/kg s.c. ketoprofen or carprofen to provide analgesia.
Only those rats that had recovered their pre-surgery weight
were studied. At the end of each study, rats were killed by
injection of pentobarbitone and their muscles rapidly
dissected and freeze-clamped.
In vivo electrotransfer
In vivo electrotransfer (IVE) was carried out under anaesthesia
and simultaneously with cannulation surgery where appli-
cable. Preparation and injection of DNA and electrotransfer
was carried out as described previously (Cleasby et al. 2005),
with 2 times 0.25 ml injections of 120 IU/ml hyaluronidase
(Sigma) administered to each muscle 2 h before IVE. Tibialis
cranialis muscles (TCMs) were injected percutaneously with
six spaced 50 ml aliquots of DNA prepared in endotoxin-free
sterile saline (Qiagen kit) at 0.5 mg/ml. For over-expression
(OE)studies,rightmuscleswereinjectedwithEH114-APPL1
and left muscles with EH114-EGFP vector as within-animal
control. To silence APPL1 expression, 0.5 mg/ml of each
APPL1 shRNA vector and 1 mg/ml of scrambled shRNA
vector were injected into right and left TCMs respectively.
Immediatelyafterwards,one 800 V/cm100 mselectrical pulse
and four 80 V/cm 100 ms pulses at 1 Hz were administered
across the distal limb via tweezer electrodes attached to an
ECM-830 electroporator (BTX, Holliston, MA, USA).
Assessment of in vivo glucose metabolism in rats
under HEC conditions
Conscious rats were studied after 5–7 h fasting. Jugular
cannulae were connected to infusion and sampling lines
between 0830 and 0930 h and the rats were left to acclimatise
for 30–40 min. HECs were conducted as described (Kraegen
et al. 1983), using a constant insulin infusion rate of 1.25 U/h,
commensurate with the generation of normal postprandial
plasma levels. Blood was withdrawn every 10 min for the
determination of glucose using a YSI 2300 glucose/lactate
analyser (YSI Life Sciences, Yellow Springs, OH, USA)
and the infusion rate of 30% glucose adjusted to maintain
euglycaemia. A combined bolus injection of 2-deoxy-D-
[2,6-
3H]glucose and D-[U-
14C]glucose (GE Healthcare,
Little Chalfont, UK) was administered once euglycaemia
was achieved, 45 min before the end of the clamp. Plasma
glucose tracer disappearance was used to calculate whole-
body glucose disposal (Rd). Endogenous glucose output
(EGO) was derived from the difference between Rd and the
net glucose infusion rate (GIR). The area under the tracer
disappearance curve of 2-deoxy-D-[2,6-
3H]glucose, together
with the disintegrations per minute of phosphorylated
[
3H]deoxyglucose from individual muscles, was used to
calculate insulin-stimulated glucose metabolic index (Rg0),
an estimate of tissue glucose uptake (Kraegen et al. 1985).
Biochemical assays
During clamps, plasma was immediately obtained from
withdrawn blood by centrifugation and frozen for sub-
sequent plasma insulin determination by RIA (Linco
Research, Inc., St Charles, MO, USA). Triglyceride was
extracted from TCMs (Bligh & Dyer 1959) and measured
using a Peridochrom Triglyceride GPO-PAP kit (Boeh-
ringer Mannheim). Muscle glycogen was extracted and
analysed as described previously (Chan & Exton 1976). Rate
of synthesis of glycogen and triglycerides was determined
from the D-[U-
14C]glucose tracer disappearance curve and
counts of [
14C] in the extracted muscle glycogen and
triglycerides as described previously (Kraegen et al. 1985).
Ceramide content of muscles was assessed using the method
of Preiss et al. (1986).
Muscle lysates, SDS-PAGE and immunoblotting
Protein expression and phosphorylation of molecules present
in muscle were assessed by SDS-PAGE and quantiﬁcation of
western blots of a minimum of nZ7 tissue lysates, typically in
duplicate. Whole muscle lysates were prepared from muscle
powdered under liquid nitrogen by manual homogenisation
in RIPA buffer (65 mmol/l Tris, 150 mmol/l NaCl,
5 mmol/l EDTA, pH 7.4, 1% (v/v) NP-40 detergent, 0.5%
(w/v) sodium deoxycholate, 0.1% (w/v) SDS, 10% (v/v)
glycerol, containing 25 mg/ml leupeptin, 10 mg/ml aprotinin,
2 mmol/l sodium orthovanadate, 10 mmol/l NaF and
1 mmol/l polymethylsulphonyl ﬂuoride) followed by rotation
for 90 min at 4 8C and centrifugation for 10 min at 16 000 g.
Protein content of supernatants was quantiﬁed using the
Bradford method (Bio-Rad Laboratories), normalised to the
lowest concentration and aliquots containing 20–80 mg
protein denatured in Laemmli buffer for 10 min at 65 8C.
Proteins were resolved by SDS-PAGE, electrotransferred and
immunoblotted as described previously (Cleasby et al. 2004).
Speciﬁc bands were detected using chemiluminescence
(Western Lightning Plus, Perkin Elmer, Seer Green, UK)
on Fuji Super RX ﬁlm (Bedford, UK), scanned and
quantiﬁed using Quantity One software (Bio-Rad). Anti-b
actin blots for each set of muscle lysates were used to conﬁrm
the lack of differences in total protein content between
treatment groups.
Statistical analysis
Data are obtained as meanGS.E.M. Comparisons between
treated and control muscles in the same animal were
made using paired Student’s t-tests and between chow- and
HFD-fed rats using unpaired t-tests. Comparisons between
HFD- and chow-fed rats subsequently electroporated were
made by two-way ANOVA with one repeated measure
(comparison between limbs). Post hoc analysis was undertaken
using the Holm-Sidak test, together, where appropriate,
with the paired or unpaired Student’s t-test to elucidate
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v3.00 (SPSS, Inc., Chicago, IL, USA), with P!0.05 regarded
as signiﬁcant.
Results
APPL1 OE and silencing in rat TCMs in vivo
IVE of EH114-GW-APPL1 was used to over-express APPL1
in the right TCMs of cohorts of chow-fed young adult rats,
with EH114-EGFP administered to the left TCMs as paired
control. After 1 week, immunoblotting of muscle lysates
conﬁrmed that APPL1 protein was successfully over-
expressed by a mean 188% (nZ10; P/0.001; Fig. 1A).
Immunoblotting for EGFP and the FLAG tag attached to the
APPL1 cDNA conﬁrmed the expression of control and
exogenous APPL1 protein in the appropriate muscles. APPL2
protein levels were unaffected by this manipulation (Fig. 1B).
IVE of APPL1-targeting shRNAs into TCMs of a parallel
cohort of chow-fed rats was used to examine the effects of
knocking down this protein in muscle. As shown in Fig. 1C,
we achieved a mean 22.5% reduction in APPL1 expression in
test versus control muscles (nZ15; P!0.001). However, this
was accompanied by a 19.4% reduction in APPL2 protein
(PZ0.0026; Fig. 1D), despite the speciﬁcity of the APPL1
targeting sequences used in the shRNA constructs and the
apparent lack of cross-reactivity of the antibody.
One week after IVE, no differences in muscle mass or
cross-sectional area of ﬁbres in transverse section were
detected, implying no effect of this level of APPL1 silencing
on cellular growth or proliferation (data not shown).
OE and silencing of APPL1 expression results in parallel
changes in glycogen storage in muscles
To establish whether altering expression of APPL1 would
have an effect on net energy storage in muscle, we measured
glycogen content of pairs of TCMs removed from APPL1
cDNA- and shRNA-electroporated rats. APPL1 OE
increased glycogen content in TCMs by 19% (PZ0.048;
Fig. 2A), reﬂecting an increase in net glycogen accumulation
during the week of the experiment. Consistent with this
change, we also identiﬁed a 26% reduction in glycogen
content of muscles in which APPL1 expression had been
knocked down (PZ0.003; Fig. 2B). Thus, APPL1 positively
impacts on glycogen stores in skeletal muscle.
APPL1 OE also increases phosphorylation of key PI3-kinase
signalling pathway intermediates in the absence of an effect on
ceramide content
We hypothesised that activation of the PI3-kinase pathway
may mediate the observed effects of APPL1 on glycogen
accumulation in muscle (Mao et al. 2006, Saito et al. 2007,
Schenck et al. 2008, Cheng et al. 2009) in vivo. Thus, we
examined the expression and phosphorylation of key
intermediates in the PI3-kinase pathway in lysates from
APPL1 over-expressing and control muscles. APPL1 OE
caused a mean 50% (P!0.001) increase in pY608-IRS1
(the rat equivalent of human pY612), together with a 25%
increase (P!0.001) in Ser473 phosphorylation of AKT, a
15% increase (PZ0.012) in pS9-GSK3b and a 47% increase
in Thr642-phosphorylation of TBC1D4 (AS160; PZ0.028),
respectively, in test versus control muscles (Fig. 3A and B).
These increases in phosphorylation are consistent with
increased ﬂux through the PI3-kinase pathway, culminating
in increased translocation of GLUT4-containing vesicles
into sarcolemma (Larance et al. 2005) and disinhibition of
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Figure 1 Modulation of APPL1 protein levels in single tibialis
cranialis muscles of rats by in vivo electrotransfer (IVE). IVE of
APPL1 cDNA-containing or APPL1-targeting shRNA constructs
was used to over-express or silence APPL1 expression in tibialis
cranialis muscles (TCMs) of chow-fed rats. After 1 week, successful
(A) over-expression of APPL1 (nZ10) was demonstrated by
immunoblotting of tissue lysates derived from test and control
TCMs. (B) APPL2 protein expression was unaffected by this
manipulation. (C) Successful down-regulation (nZ8) of APPL1 as
a result of shRNA electroporation. (D) APPL2 protein was also
reduced by APPL1 shRNA administration. Typical immunoblots for
APPL1, APPL2, the FLAG tag attached to the APPL1 cDNA and
EGFP in test (right, R, open bars) and paired control (left, L, solid
bars) muscles are shown. Data are meanGS.E.M. Paired t-testing:
**P!0.01, ***P!0.001 versus control.
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expression of IRS1 and TBC1D4 proteins were also detected
in APPL1 OE muscles, although there was no difference in
expression of b-actin between groups and the upward
regulatory trend on a phosphorylation/expression ratio basis
was preserved in each case (Fig. 3B).
In an attempt to corroborate these ﬁndings, we compared
phosphorylation and expression of the same PI3-kinase
pathway intermediates in APPL1-silenced TCMs with paired
controls and found consistent reductions in phosphoryla-
tion (pY612-IRS1, 19% reduction, PZ0.035; pS473-AKT,
21% reduction, PZ0.021; pS9-GSK3b, 12% reduction,
PZ0.023; Fig. 3C and D), which were thus complementary
to the effects of OE. Again, despite no difference in gel
loading, as indicated bya b-actin blot, a signiﬁcant decrease in
protein levels of IRS1 was detected (Fig. 3D). These
consistent changes in IRS1 expression may reﬂect effects on
proteasomal degradation rate resulting from altered serine and
tyrosine phosphorylation induced by the manipulation
(Haruta et al. 2000, Pirola et al. 2003, Cleasby et al. 2007).
However, the clear regulation by APPL1 expression levels
of phosphorylation of PI3-kinase pathway intermediates
and thus ﬂux through the pathway down to the level of
GSK3b could be sufﬁcient to explain the reduced glycogen
storage observed.
In the light of the recent demonstration that adiponectin
mediates its insulin-sensitising effects through activation of a
receptor intrinsic ceramidase activity (Holland et al. 2010), we
measured the levels of ceramides in APPL1 over-expressing
and silenced TCMs. Ceramide content was unchanged in
APPL1 OE versus control muscles (72.6G8.7v s6 9 .9
G13.3 nmol/g), whereas there was a non-signiﬁcant trend
towards APPL1 silencing resulting in increased ceramide
levels (89.8G10.1v s6 9 .7G10.0 nmol/g; PZ0.11). Thus,
these data are not suggestive that the effects of altered APPL1
expression on PI3-kinase signalling are mediated through
altered ceramide metabolism.
APPL1 OE increases insulin-stimulated muscle glycogen
synthesis in vivo and partially ameliorates HFD-induced
insulin resistance
To establish whether the APPL1-mediated increase in muscle
glycogen storage would be associated with acute increases
in insulin-stimulated glucose uptake and glycogen synthesis,
rats were subjected to a HEC combined with administration
of radiolabelled glucose and 2-deoxyglucose tracers 1 week
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Figure 2 APPL1 over-expression and silencing result in comple-
mentary changes in muscle glycogen storage. After 1 week of IVE,
glycogen content was measured in TCMs showing (A) APPL1 over-
expression (nZ10) and (B) APPL1 down-regulation (nZ8). Data are
meanGS.E.M. Glycogen was signiﬁcantly increased by APPL1
over-expression and reduced by APPL1 silencing. Panels show
results for test (open bars) and paired control (solid bars) muscles.
Paired t-testing: *P!0.05, **P!0.01 versus control.
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Figure 3 APPL1 over-expression and silencing result in a respective
increase and decrease in phosphorylation of PI3-kinase pathway
signalling intermediates under basal insulin conditions. Phos-
phorylation and expression of signalling molecules were measured
in lysates prepared from paired TCMs removed from APPL1 over-
expressing (nZ10) and silenced (nZ8–15) chow-fed rats. Data are
meanGS.E.M.; solid bars, left muscles; open bars, right muscles. (A)
Summary phosphorylation data from APPL1 over-expressing test
muscles normalised to controlfor Tyr612-insulin receptor substrate-
1, Ser473-AKT, Ser9-glycogen synthase kinase-3b and Thr642-
TBC1D4. Phosphorylation of all these intermediates was increased
by the manipulation. (B) Representative immunoblots of phos-
phorylated and total protein from APPL1 over-expressing (R) and
control (L) muscles. Protein expression of IRS1 and TBC1D4 was
also increased by APPL1 over-expression. (C) Summary phos-
phorylation data from APPL1 knock-down test muscles normalised
to control for Tyr612-insulin receptor substrate-1, Ser473-AKT,
Ser9-glycogen synthase kinase-3b and Thr642-TBC1D4. Phos-
phorylation of all these intermediates was decreased by the
manipulation. (D) Representative immunoblots of phosphorylated
and total protein from APPL1 knockdown (R) and control (L)
muscles. Protein expression of IRS1 was also decreased by APPL1
over-expression. Sample actin blots are also shown demonstrating
no differences in loading between sets of lysates. Paired t-testing:
*P!0.05, **P!0.01, ***P!0.001 versus control muscle.
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aimed to determine whether APPL1 OE was capable of
ameliorating muscle insulin resistance by measuring these
variables in rats that had been fed a HFD for 5 weeks before
clamping and comparing these to chow-fed animals. IVE
induced 360% (nZ18) and 271% (nZ15) increases in APPL1
expression in HFD- and chow-fed rats subsequently subjected
to HEC respectively (effect of APPL1 P!0.001; Fig. 4A).
However, there was no effect of diet on APPL1 expression
(PZ0.474).
HFD feeding caused 9.6 and 74% increases in body mass
and epididymal fat pad mass as a percentage of body mass
respectively (Table 1). Basal (5–7 h starved) plasma glucose
and insulin were also increased in HFD-fed rats (Table 1).
Clamped plasma glucose levels were similar between groups,
although total mean plasma insulin was slightly higher in
HFD rats (Table 1), as a result of higher endogenous plasma
insulin. HFD rats showed the expected reductions in GIR and
Rd and increase in EGO (Table 1), commensurate with the
induction of whole-body insulin resistance by the diet.
Glucose tracer incorporation into glycogen was attenuated
by HFD feeding in control muscles, but this effect was
abrogated by APPL1 OE (effect of IVE PZ0.016; interaction
PZ0.048; Fig. 4B), implying both an acute effect on
glycogen synthesis and an amelioration of the defect in
insulin-stimulated glycogen synthesis as a result of this
manipulation. Glucose uptake (Rg0) into TCMs during the
clamp tended to be reduced by HFD feeding (PZ0.064) but
was increased by a mean 10% across all test versus control
muscles (PZ0.050; Fig. 4C). Although these were modest
effects, it is likely that this attenuated glucose disposal, at least
in part, explains the effects of APPL1 on glycogen synthesis.
APPL1 OE caused an overall increase in muscle glycogen
content (PZ0.022), with the principal effect being in chow-
fed animals (Fig. 4D), consistent with the effect on acute
glycogen synthesis and the changes in glycogen content
described under basal insulin conditions earlier.
Effects of APPL1 on lipid accumulation were also assessed
in these animals. Glucose tracer incorporation into triglycer-
ides was lower overall in HFD rats during the clamp
(PZ0.027), mainly due to a speciﬁc attenuation of an effect
of APPL1 OE to increase this parameter (interaction
PZ0.069; Fig. 4E). Total content of triglyceride, reﬂecting
longer term effects on lipid turnover, was increased in HFD-
fed rats (PZ0.012). However, there was also a tendency
for APPL1 OE to increase triglyceride storage (PZ0.082;
Fig. 4F).
APPL1 OE further increases activation of the PI3-kinase
pathway in muscle of HEC rats
To verify that the observed increase in insulin-stimulated
glycogen synthesis was related to up-regulation of the
PI3-kinase pathway signalling in this setting, we measured
phosphorylation and expression of IRS1, AKT, GSK3b and
TBC1D4 in muscle lysates. APPL1 OE resulted in increased
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Figure 4 APPL1 over-expression in muscle increases local insulin-
stimulated glycogen accumulation and partially overcomes high-fat
diet (HFD)-induced insulin resistance. APPL1 was over-expressed
by IVE in additional cohorts of 5-week HFD (nZ18) and chow-fed
(nZ15) rats for 1 week and then insulin-stimulated disposal and
storage of glucose under hyperinsulinaemic–euglycaemic clamp
conditions were measured in paired TCMs. Data are meanGS.E.M.;
solid bars, left muscles; open bars, right muscles. (A) APPL1 protein
expression summary graph and representative blot, demonstrating
increased expression in both sets of animals (P!0.001), with no
effect of HFD on APPL1 expression. (B) Glucose incorporation into
glycogen during the clamp was increased overall by APPL1 over-
expression (PZ0.016) and there was an interaction between APPL1
expression and diet (PZ0.048). (C) Glucose uptake (Rg0)w a s
increased overall in APPL1 over-expressing (OE) muscles
(PZ0.050) and tended to be reduced by HFD (PZ0.064). (D)
Glycogen content of APPL1 OE TCMs was increased compared
with controls (PZ0.022), principally in chow-fed animals. (E)
Glucose incorporation into triglyceride during the clamp was
reduced overall by HFD feeding (PZ0.027). Interaction term
PZ0.069. (F) Triglyceride storage was increased in HFD versus
chow-fed muscles overall (PZ0.012), with a tendency for APPL1
OEalso toincreasetriglycerides(PZ0.082).CL– chowfed,control;
CR – chow fed, test; HL – HFD fed, control; HR – HFD fed, test
muscles. Post hoc analyses: *P!0.05, ***P!0.001 versus chow
control muscle;
$$$P!0.001 versus HFD control muscle;
#P!0.05,
##P!0.01 versus chow APPL1 OE muscle.
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to increased phosphorylation in TCMs from HFD-fed rats
(P!0.001; Fig. 5A). This change was accompanied by a
similar trend in IRS1 protein (PZ0.063). AKT phosphoryl-
ation at Ser473 was increased in APPL1 OE muscles
(PZ0.001; Fig. 5B) and total AKT protein was also increased
(PZ0.003; chow rats PZ0.055, HFD-fed rats PZ0.002).
Phosphorylation at Ser9 of GSK3b was also increased in
APPL1 OE muscles (P!0.001; Fig. 5C), again mainly due
to an effect in HFD-fed muscles (PZ0.001 and PZ0.002
respectively). Both phosphorylation and protein expression
of TBC1D4 were increased by APPL1 OE (PZ0.009 and
P!0.001 respectively; Fig. 5D), again principally due to an
effect in the muscles of HFD-fed rats (TBC1D4 interaction
term PZ0.049; effect of APPL1 OE in HFD-fed TCMs
PZ0.008 and P!0.001 respectively). These changes occur-
red in the absence of any differences in b-actin expression
between groups (Fig. 5E).
These ﬁndings are consistent with those observed under
basal insulin conditions and together likely explain the
demonstrated effect of APPL1 OE to increase glycogen
synthesis and thus promote glycogen accumulation in muscle.
Furthermore, it seems that APPL1 OE has an additive effect
to the high physiological levels of insulin stimulation of the
HEC to increase ﬂux through the PI3-kinase pathway.
Although in this study impairments in phosphorylation of
signalling intermediates in the PI3-kinase pathway were not
demonstrated that would fully account for the defects
observed in insulin action, the consistent increases in
phosphorylation of these signalling intermediates down to
the level of GSK3b may nevertheless represent a potential
mechanism by which APPL1 may ameliorate insulin
resistance in muscle in vivo.
APPL1 OE impairs activation of the AMPK pathway
in insulin-stimulated muscle
AMPK activation is thought to be the principal mediator
of adiponectin action in skeletal muscle (Tomas et al.2 0 0 2 ,
Yamauchi et al.2 0 0 2 , Yoon et al.2 0 0 6 ) and has been shown
to be the result of binding of liganded AdipoRs to APPL1 in
C2C12 myotubes (Mao et al.2 0 0 6 ). Therefore, to establish
whetherAMPKactivationmightalsoberesponsibleforsomeof
the effects of APPL1 OE in vivo, paired TCMs from insulin-
stimulated HFD- and chow-fed rats were immunoblotted
for AMPK protein and phosphorylation at the LKB1 target
residue, Thr172 (Hawley et al.2 0 0 3 ). HFD-feeding caused a
reduction in phosphorylation of AMPK, as would have been
predicted (Liu et al.2 0 0 6 ). However, perhaps unexpectedly
(Maoetal.20 06 ,Zhouetal.20 09 ),APPL1OEreducedAMPK
phosphorylation in chow-fed rats by a similar magnitude
(PZ0.041 effect of IVE, PZ0.006 interaction; Fig. 6A).
To establish whether these impairments in AMPK
phosphorylation resulted in downstream effects, we examined
phosphorylation of the AMPK substrate enzyme acetyl-CoA
carboxylase (ACC) at its target residue (Ser79). The results
were entirely consistent with the pT172-AMPK data, as
pS79-ACC was reduced overall by HFD feeding (PZ0.048),
but also by APPL1 OE, most signiﬁcantly in chow-fed
animals (interaction PZ0.075; Fig. 6B). ACC protein was
slightly increased overall as a result of APPL1 OE (PZ0.022;
sample blot in Fig. 6C), although protein loading, as indicated
by b-actin expression, was not different. We also measured
protein expression of PGC1a and UCP3, key AMPK-
regulated mediators of mitochondrial oxidative metabolism
(Ruderman et al. 2003). Both PGC1a (PZ0.008; Fig. 6D)
and UCP3 (PZ0.043; Fig. 6E) were reduced by APPL1 OE;
although in the case of UCP3, this appeared to be an effect
to reverse an increase in expression in high-fat-fed muscles
(interaction PZ0.048).
Thus, APPL1 OE in muscle in vivo caused phosphorylation
changes implying impaired acute activation of AMPK and
consequently increased activity of ACC and attenuated target
gene expression, implying longer term impairment of AMPK
activity. The likely increase in malonyl-CoA and impaired
b-oxidation resulting from these changes (McGarry 2002)i s
consistent with the observed tendency for increased
triglyceride storage in APPL1 OE muscles. Furthermore,
AMPK phosphorylation tended to be increased by APPL1
OE under basal insulin conditions and was signiﬁcantly
elevated by APPL1 silencing (data not shown), results
consistent with these data.
Table 1 Chow- and high-fat diet-fed rat characteristics (meanGS.E.M.) under basal and hyperinsulinaemic–euglycaemic clamp conditions
Chow fed High-fat diet fed
Basal Clamp Basal Clamp
Plasma glucose (mM) 7.5( G0.4) 8.0( G0.1) 9.1( G0.6)* 8.3( G0.1)
Plasma insulin (mU/l) 28.2( G2.7) 124.3( G8.3) 65.7( G5.1)
‡ 155.8( G6.4)
†
Body weight (BW) at study (g) 393 (G8) 428 (G8)
†
Epididymal fat pad mass (%age BW) 0.52 (G0.02) 0.91 (G0.06)
‡
Glucose infusion rate (mg/kg per min) 29.4( G1.8) 20.8( G1.3)
‡
Whole-body glucose disposal (mg/kg per min) 26.7( G2.0) 22.1( G1.8)*
Endogenous glucose output (mg/kg per min) K3.2( G1.9) 2.1( G1.2)*
*P!0.05,
†P!0.01,
‡P!0.001 versus equivalent measurement for chow-fed rats.
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This study strongly implies a role for APPL1 in enhancing
glycogen synthesis in skeletal muscle in vivo, mediated via
activation of the insulin signalling pathway. Acute local
OE of APPL1 in adult muscle resulted in increased
insulin-stimulated glycogen synthesis and correction of
HFD-induced insulin resistance of this parameter in this
critical insulin target tissue. This effect was most likely
mediated via up-regulated signalling to glucose transport and
glycogen synthesis through the PI3-kinase pathway from the
level of IRS1. In addition, we present evidence that APPL1
may be involved in attenuating AMPK-dependent pathways
in skeletal muscle, contrary to the results of previous in vitro
studies. These ﬁndings are supportive of a role for crosstalk
between the adiponectin and the insulin signalling pathways
at the level of APPL1 in mediating the insulin-sensitising
effects of adiponectin in skeletal muscle in vivo.
In this study, the degree of silencing in muscles achieved
using APPL1 shRNA seemsto be relatively modest compared
with the degree of OE induced in a separate group of animals.
However, the similarity in downstream effect renders the
opposing results readily comparable for interpretation
purposes. Our prior experience of manipulating expression
of signalling molecules such as AKT in muscle (Cleasby et al.
2007) suggests that IVE of shRNA constructs commonly
results in expression changes of lower magnitude than IVE
of OE constructs. This may be due to differences in
electrotransfer efﬁciency or expression of the constructs,
which are contained within different plasmid vectors. It is
likely that relatively small reductions in expression are capable
of adversely affecting the signalling threshold of the PI3-
kinase pathway, although large degrees of OE have relatively
more limited effects on a percentage change basis, due to
limitations in the dynamic range of the pathway (Hoehn et al.
2008, Janes et al. 2008). The effect of APPL1 shRNA
administration to also reduce APPL2 protein is intriguing.
Given the lack of effect on APPL2 after APPL1 OE, antibody
cross-reactivity would not seem to be the explanation. In
addition, a BLAST search for the APPL1 shRNA target
sequences used conﬁrms their speciﬁcity. Instead, this would
seem to be a secondary effect of APPL1 silencing and may
help to explain the magnitude of the effect of IVE of the
APPL1 shRNA construct on downstream signalling. A
possible explanation may be that reduced APPL1 protein
availability results in reduced APPL heterodimerisation,
exposing APPL2 molecules to proteasomal degradation.
However, previously published in vitro data have suggested
that APPL1 and APPL2 play antagonistic roles (Wang et al.
2009), which would make it surprising if reduced APPL2
expression had additive effects to silencing of APPL1. This
issue is discussed later.
APPL1 was ﬁrst identiﬁed as an adaptor protein that
interacts with AKT2 and plays a role in its recruitment to the
plasma membrane (Mitsuuchi et al. 1999). The discovery of
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Figure 5 APPL1 over-expression has an additive effect to high
physiological levels of insulin to activate the PI3-kinase pathway.
Expression and phosphorylation at key residues of intermediates
in the PI3-kinase pathway were measured by immunoblotting of
lysates of paired TCMs from chow- (nZ12–18) and HFD-
(nZ10–15) fed hyperinsulinaemic–euglycaemic clamped rats.
Data are meanGS.E.M.; solid bars, left muscles; open bars, right
muscles. (A) Tyr612 phosphorylation of IRS1 was increased by
APPL1 over-expression (OE) (P!0.001). (B) Ser473 phosphoryl-
ation of AKTwas also increased by APPL1 OE (PZ0.001). (C) Ser9
phosphorylation of GSK3b was also greater in APPL1 over-
expressing muscles (P!0.001). (D) Thr642 phosphorylation of
TBC1D4 was increasedbyAPPL1 OE (PZ0.009). (E)Representative
immunoblots of phosphorylated and total protein from CL – chow
fed, control; CR – chow fed, test; HL – HFD fed, control; HR – HFD
fed, test muscles. There was a tendency for IRS1 protein to be
increased by APPL1 OE (PZ0.063), whereas AKT protein was
increased overall by APPL1 OE (PZ0.003) and showed a tendency
to be decreased by HFD feeding (PZ0.085). TBC1D4 protein was
also increased (P!0.001), with an interaction between diet and OE
effects (PZ0.049), showing a larger effect in the HFD-fed animals.
However, an actin loading control blot is also shown, demonstrat-
ing that loading was not different among samples. Post hoc
analyses: *P!0.05 versus chow control muscle;
$P!0.05,
$$P!0.01,
$$$P!0.001 versus HFD control muscle.
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mediating downstream effects of adiponectin (Mao et al.
2006), coupled with a demonstration of the requirement of
the APPL1/AKT2 interaction for full insulin-stimulated
GLUT4 translocation in adipocytes (Saito et al. 2007), raised
the intriguing possibility that APPL1 may provide a key node
for interaction between the PI3-kinase pathway and the
putative adiponectin signalling pathway (Mao et al. 2006).
The increased phosphorylation of key intermediates in the
PI3-kinase pathway (IRS1, AKT, TBC1D4 and GSK3) in
APPL1 OE muscles under basal and insulin-stimulated
conditions and the complementary reductions observed
after APPL1 silencing demonstrate that activation of this
pathway can be achieved via APPL1, and with additive effects
to those of insulin alone, under physiological conditions in
muscle. This is consistent with a recent study that
demonstrated an additive effect of adiponectin to that of
insulin in stimulating IRS1 and AKT phosphorylation in L6
myotubes (Fang et al. 2009). In a previous study, treatment of
cultured myotubes with adiponectin enhanced the ability
of insulin to activate the PI3-kinase pathway because of
disinhibition of IRS1 tyrosine phosphorylation due to
reduced AMPK-mediated activation of the serine kinase
p70S6 kinase (Wang et al. 2007). However, the opposite
effects observed on the activation of AMPK imply that an
alternative mechanism is operative in muscle in vivo. Never-
theless, in our study, altered APPL1 expression also had effects
on the PI3-kinase pathway from the level of IRS1, and in
addition, we were unable to demonstrate a quantiﬁable
interaction between AKT and APPL1 by co-immunopreci-
pitation of muscle lysates (data not shown), suggesting that
APPL1 may interact with a more proximal binding partner in
the pathway in this context.
In this study, we were unable to demonstrate that the effects
of altered APPL1 expression on signalling were mediated
by alterations in ceramide content, the recently proposed
mechanism for the effects of ligand binding by AdipoRs
(Holland et al. 2010). This would be consistent with the
effects of altered APPL1 expression being mediated through
binding to downstream signalling molecules rather than
AdipoRs. APPL1 OE also caused changes in protein
expression of some of the signalling intermediates measured.
This may reﬂect translational or pre-translational effects of
APPL1, perhaps exerted by regulation of transcription factors,
analogous to the effects of APPL1 OE recently observed on
b-catenin/TCF (Rashid et al. 2009) or in the case of IRS1,
and islikely to be the result of alteredproteasomal degradation
rates, secondary to changes in phosphorylation (Haruta et al.
2000, Pirola et al. 2003, Cleasby et al. 2007). The lack of a
complementary down-regulatory effect on TBC1D4 protein
in the shRNA-electroporated muscles is likely to reﬂect
relatively lower sensitivity of this mechanism to silencing than
that of the PI3-kinase phosphorylation cascade. Nevertheless,
it seems likely that APPL1 OE represents a state of increased
ﬂux through the proximal adiponectin signalling pathway
and thus these ﬁndings implicate APPL1 as a key node for
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Figure 6 APPL1 over-expression reduces activation of AMP-
activated protein kinase in muscle from hyperinsulinaemic–
euglycaemic clamped rats. Phosphorylation and expression of
AMPK and downstream substrates were measured by immuno-
blotting of lysates of paired TCMs from chow- (nZ12–18) and
HFD- (nZ10–15) fed hyperinsulinaemic–euglycaemic clamped
rats. Data are meanGS.E.M.; solid bars, left muscles; open bars, right
muscles. (A) Thr172 phosphorylation of AMPK was reduced overall
by APPL1 over-expression (OE) (PZ0.041) to a similar extent to the
reduction caused by diet (interaction PZ0.006). (B) Serine79
phosphorylation of ACC was reduced overall as a result of both
APPL1 OE (P!0.001) and HFD feeding (PZ0.048); interaction
PZ0.075. (C) Representative immunoblots of phosphorylated
and total protein from CL – chow fed, control; CR – chow fed, test;
HL – HFD fed, control; HR – HFD fed, test muscles. ACC protein
expression was slightly increased overall by APPL1 OE (PZ0.022).
Levels of actin were not different between treatment groups.
(D) PGC1a protein was reduced overall by APPL1 OE (PZ0.008).
(E) UCP3 was also reduced overall by APPL1 OE (PZ0.043) but
principally due to normalisation of an increase in expression due to
HFD feeding (interaction PZ0.048). Post hoc analyses: *P!0.05,
**P!0.01 versus chow control muscle;
$P!0.05,
$$P!0.01 versus
HFD control muscle.
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insulin-sensitising effect of adiponectin in muscle.
Although PI3-kinase signalling was not signiﬁcantly
impaired in the moderate duration HFD-fed rat model
used in this study, OE of APPL1 largely had its stimulatory
effects in the muscles of HFD-fed animals, suggesting that
therapeutic insulin sensitisation could be engineered in
insulin-resistant states through this molecule. This assertion
is supported on a metabolic level by the correction of HFD-
impairedinsulin-stimulatedglycogensynthesisbyAPPL1OE,
although the improvement in acute glucose uptake is modest
and appears to occur irrespective of dietary status. However, a
signiﬁcant potential risk in targeting this molecule thera-
peutically is likely to be its relative promiscuity in phosphoi-
nositide and protein binding partners and the as yet poorly
characterised cellular implications of its activation. Indeed,
APPL1 has been shown to interact with APPL2 (Chial et al.
2008), Rab5 (Miaczynska et al. 2004), histone deacetylases
(Miaczynskaetal.2004,Rashidetal.2009),AKT2(Mitsuuchi
et al. 1999, Saito et al. 2007), AdipoRs (Mao et al. 2006) and
TrkA and GIPC1 (Lin et al. 2006), thus being implicated in
cellular growth and proliferation, in addition to metabolism.
Adiponectin is generally thought to achieve its effects on
glucose disposal and fatty acid oxidation through AMPK
activation in muscle (Yamauchi et al. 2002, Yoon et al. 2006,
Wangetal.2007,Zhouetal.2009)andthemechanismhasbeen
shown to involve APPL1 in myotubes in culture (Mao et al.
2006, Zhou et al. 2009). However, the role of APPL1 in
AMPK activation has not previously been investigated in
muscle in vivo. In this study, APPL1 OE resulted in similar
signiﬁcant reductions in phosphorylation of both AMPK and
its target ACC during HEC to those caused by an HFD. This
ﬁnding certainly implies that in this context the beneﬁcial
effects of muscle APPL1 OE on glucose disposal and glycogen
synthesis are not exerted through AMPK, but more likely
through the demonstrated increases in TBC1D4 and GSK3
phosphorylation. However, it is possible that the increased
levels of muscle glycogen may contribute to the reduced
AMPK phosphorylation (McBride et al. 2009). Nevertheless,
the decreases in expression of both PGC1a and UCP3, the
tendency for APPL1 OE muscles to accumulate more
triglycerideandthecomplementaryeffectsofAPPL1silencing
are consistent with the effects of APPL1 OE on AMPK and
ACC activation and suggest that the effect on AMPK is not
purely acute in nature and related to inhibition by high
physiological levels of insulin during the HEC (Kovacic et al.
2003). Instead, these data suggest that APPL1 may play dual
rolestoincreaseglucosedisposalintomusclewhileattenuating
AMPK-mediated mitochondrial fatty acid oxidation.
APPL2 has been shown to have a similar role to APPL1 in
mediating cell proliferation (Miaczynska et al. 2004) and
b-catenin/TCF-dependent transcription (Rashid et al. 2009),
but a recent report suggested that APPL2 competes with
APPL1 for binding to AdipoR1 in myotubes and thus has an
antagonistic effect on adiponectin and insulin signalling
(Wang et al. 2009). Supply of additional APPL1 to muscle
cells may, therefore, have its beneﬁcial effects due to a shift
in the APPL1:APPL2 ratio. This would seem to make it less
likely that the reduction in APPL2 protein induced in
addition to APPL1 silencing would have an additive effect on
PI3-kinase signalling or glycogen accumulation. In addition,
it is possible that adiponectin-mediated AMPK activation
and consequent fatty acid use may involve APPL2 in muscle,
whereas APPL1 mediates an inhibitory effect, analogous to
the differential effector activation shown to be mediated
through adiponectin binding to AdipoR1 and AdipoR2 in
the liver (Yamauchi et al. 2007). It is clear that further work
is necessary to establish the metabolic roles of putative
adiponectin signalling molecules in insulin target tissues in
relevant physiological settings.
In conclusion, APPL1 promotes glucose disposal into
skeletal muscle in vivo through activation of the PI3-kinase
pathway. This adaptor protein may provide a means of
crosstalk between insulin and adiponectin signalling pathways
and thus a means for the insulin-sensitising effect of
adiponectin in muscle in vivo. Furthermore, OE of this
molecule is capable of partially ameliorating muscle insulin
resistance in a relevant physiological setting. Further work is
required to more fully delineate the signalling networks
integrated by this scaffolding protein with a view to establish
whether it may provide a suitable target for novel therapeutic
interventions aimed at ameliorating type 2 diabetes.
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